Clinical Benefits of a Metabolic Approach in the Cardiac Rehabilitation of Patients with Coronary Artery Disease

Belardinelli, Romualdo; Lacalaprice, Francesca; Faccenda, Ernesto; Volpe, Loretta

doi:10.1016/j.amjcard.2006.07.006

Cited by 11 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A more marked increase in radial artery diameter to acetylcholine infusion was observed in patients receiving TMZ who had two or more coronary risk factors [21]. A possible explanation may be that such patients have a greater oxidative stress, as demonstrated by the higher plasma levels of malondialdehyde and lipid hydroperoxides than normal controls, and severe endothelial dysfunction.…”

Section: Discussionmentioning

confidence: 92%

Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation

Belardinelli¹,

Lacalaprice²,

Faccenda³

et al. 2008

European Journal of Cardiovascular Prevention & Rehabilitat

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 92%

Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation

Belardinelli¹,

Lacalaprice²,

Faccenda³

et al. 2008

European Journal of Cardiovascular Prevention & Rehabilitat

Self Cite

View full text Add to dashboard Cite

show abstract

“…TMZ has been shown to maintain the contractile response of the myocardium under transitory hypoxia, because glucose as substrate reduces its demand for oxygen while maintaining its metabolic rate and viability . Accordingly, improving cardiac energy metabolism via metabolic modulators has a beneficial effect in patients with ischemic cardiomyopathy; prometabolic drugs such as TMZ are therefore commonly used as monotherapy or adjunctive therapy for the treatment of chronic stable angina . In addition to its anti‐ischemic role, we have recently reported that TMZ improves exercise capability in patients suffering from chronic stable angina .…”

Section: Introductionmentioning

confidence: 99%

The metabolic modulator trimetazidine triggers autophagy and counteracts stress‐induced atrophy in skeletal muscle myotubes

Ferraro¹,

Giammarioli

Caldarola

et al. 2013

The FEBS Journal

View full text Add to dashboard Cite

It has recently been demonstrated that trimetazidine (TMZ), an anti-ischemic antianginal agent, is also able to improve exercise performance in patients with peripheral arterial disease. TMZ is a metabolic modulator, and the mechanisms underlying its cytoprotective anti-ischemic activity could be ascribed, at least in cardiomyocytes, to optimization of metabolism. However, regarding the cytoprotection exerted by TMZ on skeletal muscle and allowing the improvement of exercise performance, no information is yet available. In the present study, we investigated in detail the protective effects of this drug on in vitro skeletal muscle models of atrophy. Experiments carried out with murine C2C12 myotubes treated with TMZ revealed that this drug could efficiently counteract the cytopathic effects induced by the proinflammatory cytokine tumor necrosis factor-a and by the withdrawal of growth factors. Indeed, TMZ significantly counteracted the reduction in myotube size induced by these treatments. TMZ also increased myosin heavy chain expression and induced hypertrophy in C2C12 myotubes, both effects strongly suggesting a role of TMZ in counteracting atrophy in vitro. In particular, we found that TMZ was able to activate the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin 2 pathway and to reduce the stress-induced transcriptional upregulation of atrogin-1, muscle ring finger protein 1, and myostatin, all of which are key molecules involved in muscle wasting. Moreover, this is the first demonstration that TMZ induces autophagy, a key mechanism involved in muscle mass regulation. On the basis of these results, it can be hypothesized that the improvement in exercise performance previously observed in patients could be ascribed to a cytoprotective mechanism exerted by TMZ on skeletal muscle integrity.

show abstract

“…На сегодняшний день накоплен целый ряд доказательств, что триметазидин в комплексе с гемодинамической терапи-ей оказывает благоприятное влияние на фракцию выбро-са (ФВ) левого желудочка (ЛЖ) у пациентов с ишемиче-ской кардиомиопатией и систолической дисфункцией ЛЖ. Так, достоверное увеличение ФВ ЛЖ без существен-ных изменений перфузии миокарда было отмечено при терапии триметазидином у больных с ХСН ишемического генеза и сопутствующим сахарным диабетом (СД) 2-го типа в течение 3 месяцев [12].…”

Section: сердечная недостаточностьunclassified

Myocardial Cytoprotector Trimetazidine Mb-Preparat, Increases the Effectiveness of Treatment of Chronic Heart Failure and Coronary Heart Disease

Трухан¹,

Давыдов²,

Мазуров³

2017

Med. sov.

View full text Add to dashboard Cite

Clinical Benefits of a Metabolic Approach in the Cardiac Rehabilitation of Patients with Coronary Artery Disease

Cited by 11 publications

References 34 publications

Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation

Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation

The metabolic modulator trimetazidine triggers autophagy and counteracts stress‐induced atrophy in skeletal muscle myotubes

Myocardial Cytoprotector Trimetazidine Mb-Preparat, Increases the Effectiveness of Treatment of Chronic Heart Failure and Coronary Heart Disease

Contact Info

Product

Resources

About